FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135698906> ?p ?o ?g. }

• W3135698906 endingPage "295" @default.
• W3135698906 startingPage "295" @default.
• W3135698906 abstract "295 Background: Ipilimumab and Nivolumab (I+N) is now an established first line option for patients with advanced RCC of intermediate (I) or poor (P) IMDC risk score. In this retrospective review, we review our experience of this combination in two cancer centres in North West England with a focus on immune related adverse events (irAEs) and their impact on the patient pathway. Methods: Treatment naïve mRCC patients starting I+N between May 2019 and July 2020 were identified. Primary outcomes of interest include overall response rate (ORR), the management of irAEs and early survival observations. Results: A total of 69 patients were identified. Median age was 60yr (19-82yr), 77% had clear cell histology. The IMDC risk was 72% I and 28% P. Median follow-up was 11.0 mo (1-22mo). ORR was 45% (CR 9%, PR 36%, SD 28%, PD 23%, NE 4%) Median time to first response was 2.9mo. (1.8- 15.5mo). 10% of patients experienced pseudoprogression. Median PFS and OS are not yet reached with 86% of patients still alive at the time of data cut-off. The majority (75%) of patients completed all 4 doses of I+N. Of the 10% receiving less than 4 doses due to toxicity, 14% continued on single agent N. Overall, 15% discontinued therapy due to toxicity and 28% experienced at least one treatment delay. Any grade irAEs were seen in 74% of patients (G3 35%) with no treatment related deaths. The commonest irAEs were: rash/pruritis 39%; endocrinopathies 30%(G3 7%); diarrhoea 29% (G3 14%); hepatitis 22% (G3 6%); and nephritis 3% (G3 3%). Of the patients developing irAEs, 71% received steroids with 16% requiring additional immunosuppression including infliximab (6%) and mycophenolate mofetil (8%). A third of all patients required admission for irAE management with a total of 37 inpatient episodes across the cohort with a median length of 7 days (1-24). 7% of patients proceeded to surgery for either primary or metastatic disease, which contributed to ongoing disease response in these patients. At the time of data cut-off, 45% of patients were no longer on treatment due to PD (29%), toxicity (15%) or unrelated death (1%). Of those who stopped due to toxicity, 50% subsequently progressed with a median time to progression of 4mo (3-6 mo) and 50% remain on active surveillance with a median follow-up of 7.5mo (1-10). 62% of patients with PD received second line treatment; most frequently, cabozantinib (83%). Conclusions: Our experience of I+N shows comparable efficacy and toxicity profiles to available reports. irAEs requiring intervention are frequent and may be associated with prolonged hospital admission, and patients should be counselled appropriately. Data within mirrors published reports of ongoing responses in a subset of patients who stop treatment due to toxicity and also suggests a possible role for resection of residual or metastatic disease in disease control. Updated survival data will be presented." @default.
• W3135698906 created "2021-03-15" @default.
• W3135698906 creator A5037026052 @default.
• W3135698906 creator A5067724726 @default.
• W3135698906 creator A5070603865 @default.
• W3135698906 creator A5083525982 @default.
• W3135698906 date "2021-02-20" @default.
• W3135698906 modified "2023-10-14" @default.
• W3135698906 title "Ipilimumab and nivolumab (I+N) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world review in North West of England, United Kingdom." @default.
• W3135698906 doi "https://doi.org/10.1200/jco.2021.39.6_suppl.295" @default.
• W3135698906 hasPublicationYear "2021" @default.
• W3135698906 type Work @default.
• W3135698906 sameAs 3135698906 @default.
• W3135698906 citedByCount "1" @default.
• W3135698906 countsByYear W31356989062022 @default.
• W3135698906 crossrefType "journal-article" @default.
• W3135698906 hasAuthorship W3135698906A5037026052 @default.
• W3135698906 hasAuthorship W3135698906A5067724726 @default.
• W3135698906 hasAuthorship W3135698906A5070603865 @default.
• W3135698906 hasAuthorship W3135698906A5083525982 @default.
• W3135698906 hasConcept C121608353 @default.
• W3135698906 hasConcept C126322002 @default.
• W3135698906 hasConcept C141071460 @default.
• W3135698906 hasConcept C197934379 @default.
• W3135698906 hasConcept C2777472916 @default.
• W3135698906 hasConcept C2777701055 @default.
• W3135698906 hasConcept C2778570526 @default.
• W3135698906 hasConcept C2780030458 @default.
• W3135698906 hasConcept C2781433595 @default.
• W3135698906 hasConcept C29730261 @default.
• W3135698906 hasConcept C71924100 @default.
• W3135698906 hasConceptScore W3135698906C121608353 @default.
• W3135698906 hasConceptScore W3135698906C126322002 @default.
• W3135698906 hasConceptScore W3135698906C141071460 @default.
• W3135698906 hasConceptScore W3135698906C197934379 @default.
• W3135698906 hasConceptScore W3135698906C2777472916 @default.
• W3135698906 hasConceptScore W3135698906C2777701055 @default.
• W3135698906 hasConceptScore W3135698906C2778570526 @default.
• W3135698906 hasConceptScore W3135698906C2780030458 @default.
• W3135698906 hasConceptScore W3135698906C2781433595 @default.
• W3135698906 hasConceptScore W3135698906C29730261 @default.
• W3135698906 hasConceptScore W3135698906C71924100 @default.
• W3135698906 hasIssue "6_suppl" @default.
• W3135698906 hasLocation W31356989061 @default.
• W3135698906 hasOpenAccess W3135698906 @default.
• W3135698906 hasPrimaryLocation W31356989061 @default.
• W3135698906 hasRelatedWork W1251229738 @default.
• W3135698906 hasRelatedWork W2750661428 @default.
• W3135698906 hasRelatedWork W2890327592 @default.
• W3135698906 hasRelatedWork W2928025315 @default.
• W3135698906 hasRelatedWork W2954433741 @default.
• W3135698906 hasRelatedWork W2977436503 @default.
• W3135698906 hasRelatedWork W3005150264 @default.
• W3135698906 hasRelatedWork W3175085288 @default.
• W3135698906 hasRelatedWork W4255880847 @default.
• W3135698906 hasRelatedWork W4313404390 @default.
• W3135698906 hasVolume "39" @default.
• W3135698906 isParatext "false" @default.
• W3135698906 isRetracted "false" @default.
• W3135698906 magId "3135698906" @default.
• W3135698906 workType "article" @default.